Kinetic Evaluation of Determinant Factors for Cellular Accumulation of Protoporphyrin IX Induced by External 5-Aminolevulinic Acid for Photodynamic Cancer Therapy

Nakanishi, Takeo; Ogawa, Tetsuro; Yanagihara, Chihiro; Tamai, Ikumi

doi:10.1002/jps.24462

Cited by 17 publications

(14 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FDA-approved drug library Japan version (CB-BML-2841J0100, Enzo Life Sciences Inc., Farmingdale, NY) was provided by Kanazawa University Cancer Research Institute. [5,6,8,11,12,14,…”

Section: Methodsmentioning

confidence: 99%

“…HEK293 cells transfected with vector pcDNA3.1 (Invitrogen, Carlsbad, CA) alone (Mock) or SLCO2A1 cDNA (HEK/2A1), and human lymphoma U-937 cells were prepared as described previously. 13,14 Physicochemical Properties of Drugs Oil-water partition coefficient (logP) and acid dissociation constant (pKa) were obtained from SciFinder database (American Chemical Society, Columbus, OH).…”

Section: Cell Culturementioning

confidence: 99%

See 1 more Smart Citation

Impact of FDA-Approved Drugs on the Prostaglandin Transporter OATP2A1/SLCO2A1

Kamo

Nakanishi

Aotani

et al. 2017

Journal of Pharmaceutical Sciences

Self Cite

View full text Add to dashboard Cite

“…FDA-approved drug library Japan version (CB-BML-2841J0100, Enzo Life Sciences Inc., Farmingdale, NY) was provided by Kanazawa University Cancer Research Institute. [5,6,8,11,12,14,…”

Section: Methodsmentioning

confidence: 99%

Section: Cell Culturementioning

confidence: 99%

Impact of FDA-Approved Drugs on the Prostaglandin Transporter OATP2A1/SLCO2A1

Kamo

Nakanishi

Aotani

et al. 2017

Journal of Pharmaceutical Sciences

Self Cite

View full text Add to dashboard Cite

“…Theoretically, enhanced ALA-PpIX in tumor cells can be caused by factors including elevated ALA uptake, enhanced porphyrin importer activity and decreased PpIX exporter activity. Although enhanced ALA uptake has been shown in tumor cells with elevated PpIX [ 36 ], more studies demonstrate that the difference in ALA uptake between higher and lower PpIX producing cell lines is not significant [ 23 , 41 , 47 ] and the rate of ALA uptake is far greater than PpIX synthesis [ 48 ], indicating that ALA uptake does not appear to be a determining factor for enhanced ALA-PpIX in tumor cells.…”

Section: Mechanisms Involved In Enhanced Ppix Production and Accummentioning

confidence: 99%

Aminolevulinic Acid-Based Tumor Detection and Therapy: Molecular Mechanisms and Strategies for Enhancement

Yang

Palasuberniam

Kraus

et al. 2015

IJMS

135

120

View full text Add to dashboard Cite

Aminolevulinic acid (ALA) is the first metabolite in the heme biosynthesis pathway in humans. In addition to the end product heme, this pathway also produces other porphyrin metabolites. Protoporphyrin (PpIX) is one heme precursor porphyrin with good fluorescence and photosensitizing activity. Because tumors and other proliferating cells tend to exhibit a higher level of PpIX than normal cells after ALA incubation, ALA has been used as a prodrug to enable PpIX fluorescence detection and photodynamic therapy (PDT) of lesion tissues. Extensive studies have been carried out in the past twenty years to explore why some tumors exhibit elevated ALA-mediated PpIX and how to enhance PpIX levels to achieve better tumor detection and treatment. Here we would like to summarize previous research in order to stimulate future studies on these important topics. In this review, we focus on summarizing tumor-associated alterations in heme biosynthesis enzymes, mitochondrial functions and porphyrin transporters that contribute to ALA-PpIX increase in tumors. Mechanism-based therapeutic strategies for enhancing ALA-based modalities including iron chelators, differentiation agents and PpIX transporter inhibitors are also discussed.

show abstract

“…Furthermore, studies have indicated that high and low PpIX 5-ALA absorption were not significantly different between cell lines (64,76,77). Nakanishi et al (78) demonstrated that there was no correlation between 5-ALA-induced PpIX accumulation and the uptake clearance of 5-ALA. The aforementioned study also revealed that ALA uptake rates were far greater than maximum conversion rates of ALA to PpIX in LS-180, T24, A2780, DU145 and MCF-7 cell lines.…”

Section: ‘Pro-dye’ Fluorescent Agent 5-alamentioning

confidence: 99%

Fluorescent contrast agents for tumor surgery (Review)

Xiao

Chen

2018

Exp Ther Med

View full text Add to dashboard Cite

Cancer is a leading cause of cases of mortality worldwide. The most effective method to cure solid tumors is surgery. Every year, >50% of cancer patients receive surgery to remove solid tumors. Surgery may increase the cure rate of most solid tumors by 4–11 fold. Surgery has many challenges, including identifying small lesions, locating metastases and confirming complete tumor removal. Fluorescence guidance describes a new approach to improve surgical accuracy. Near-infrared fluorescence imaging allows for real-time early diagnosis and intraoperative imaging of lesion tissue. The results of previous preclinical studies in the field of near-infrared fluorescence imaging are promising. This review provides examples introducing the three kinds of fluorescent dyes: The passive fluorescent dye indocyanine green, which has been approved by the Food and Drug Administration for clinical use in the USA, the fluorescent prodrug 5-aminolevulinic acid, a porphyrin precursor in the heme synthesis, and biomarker-targeted fluorescent dyes, which allow conjugation to different target sites.

show abstract

Kinetic Evaluation of Determinant Factors for Cellular Accumulation of Protoporphyrin IX Induced by External 5-Aminolevulinic Acid for Photodynamic Cancer Therapy

Cited by 17 publications

References 37 publications

Impact of FDA-Approved Drugs on the Prostaglandin Transporter OATP2A1/SLCO2A1

Impact of FDA-Approved Drugs on the Prostaglandin Transporter OATP2A1/SLCO2A1

Aminolevulinic Acid-Based Tumor Detection and Therapy: Molecular Mechanisms and Strategies for Enhancement

Fluorescent contrast agents for tumor surgery (Review)

Contact Info

Product

Resources

About